Quick Answer
TENAX THERAPEUTICS, INC. reported R&D Expense of $32.67 million for fiscal year 2025.
TENAX THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $32.67M | +157.1% |
| 2024 | $12.71M | +293.6% |
| 2023 | $3.23M | -40.0% |
| 2022 | $5.38M | -78.6% |
| 2021 | $25.15M | +451.4% |
| 2020 | $4.56M | +31.4% |
| 2019 | $3.47M | +180.1% |
| 2018 | $1.24M | -64.9% |
| 2017 | $3.53M | -73.2% |
| 2016 | $13.14M | +97.3% |
| 2015 | $6.66M | +122.3% |
| 2014 | $3.00M | +22.0% |
| 2013 | $2.46M | -0.3% |
| 2012 | $2.46M | -8.2% |
| 2011 | $2.68M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.33M | +231.9% | +68.7% |
| June 30, 2025 | $6.12M | +163.0% | +7.7% |
| March 31, 2025 | $5.68M | +112.4% | +82.6% |
| September 30, 2024 | $3.11M | +192.0% | +33.7% |
| June 30, 2024 | $2.33M | +1075.8% | -13.0% |
| March 31, 2024 | $2.68M | +907.0% | +151.1% |
| September 30, 2023 | $1.07M | -30.8% | +438.6% |
| June 30, 2023 | $197.9K | -87.0% | -25.5% |
- TENAX THERAPEUTICS, INC. showed an increase of +157.1% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, TENAX THERAPEUTICS, INC.’s r&d expense has grown by 1118.3% (from $2.68 million to $32.67 million).
- The most recent figure is from TENAX THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: